High-Grade Prostate Cancer: Favorable Results in the Modern Era Regardless of Initial Treatment

Table 1

Comparison of patient demographics and pretreatment features.

	Surgery	Radiation	Hormone therapy	Total	𝑃 value
Age					<0.001^1
𝑁	216	59	129	404
Mean (SD)	64.6 (7.2)	70.9 (8.4)	77 (8.1)	69.5 (9.5)
Race, 𝑁 (%)					0.48^2
White	161 (74.5)	40 (67.8)	92 (71.3)	293 (72.5)
Black	14 (6.5)	7 (11.9)	16 (12.4)	37 (9.2)
Other	3 (1.4)	0 (0)	1 (0.8)	4 (1)
Unknown	38 (17.6)	12 (20.3)	20 (15.5)	70 (17.3)
Total	216	59	129	404
Gleason score, 𝑁 (%)					0.37^2
8	84 (54.2)	33 (55.9)	63 (48.8)	180 (52.5)
9	67 (43.2)	22 (37.3)	57 (44.2)	146 (42.6)
10	4 (2.6)	4 (6.8)	9 (7)	17 (5)
Total^3	155	59	129	343
PSA at diagnosis (ng/mL)					<0.001^1
𝑁	208	57	126	391
Mean (SD)	10.3 (11.9)	15.5 (27.1)	48.2 (79.4)	23.3 (50)
Fraction of positive cores					<0.001^1
𝑁	214	59	126	399
Mean (SD)	50% (30%)	40% (30%)	60% (30%)	50% (30%)

¹Kruskal-Wallis Test.
²Pearson’s Chi-Square Test.
³61 surgical patients had a Gleason score of <8 on biopsy but ≥8 on radical prostatectomy pathology and thus were included for analysis.